X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Alpha Dart (radium-224) is designed to enable highly potent and conformal alpha-irradiation of solid tumors by intratumoral delivery of radium-224 impregnated sources.
Lead Product(s): Radium-224
Therapeutic Area: Oncology Product Name: Alpha Dart
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 17, 2023
Details:
Alpha DaRT (radium-224) is designed to enable highly potent and conformal alpha-irradiation of solid tumors by intratumoral delivery of radium-224 impregnated sources. When the radium decays it emitts high-energy alpha particles with the goal of destroying the tumor.
Lead Product(s): Radium-224
Therapeutic Area: Oncology Product Name: Alpha Dart
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 03, 2023
Details:
Alpha DaRT (radium-224) is designed to enable highly potent and conformal alpha-irradiation of solid tumors by intratumoral delivery of radium-224 impregnated sources. When the radium decays it emitts high-energy alpha particles with the goal of destroying the tumor.
Lead Product(s): Radium-224
Therapeutic Area: Oncology Product Name: Alpha Dart
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 01, 2023
Details:
Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is designed to enable highly potent and conformal alpha-irradiation of solid tumors by intratumoral delivery of radium-224 impregnated sources.
Lead Product(s): Radium-224,Temozolomide
Therapeutic Area: Oncology Product Name: Alpha Dart
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 08, 2022
Details:
Alpha DaRT is based on inserting directly into tumor small amounts of radium-224 affixed to metal sources designed to decay and release radioactive atoms that diffuse inside tumor, emitting alpha radiation that aims to damage and kill cancer cells within short period.
Lead Product(s): Radium-224
Therapeutic Area: Oncology Product Name: Alpha Dart
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 05, 2022
Details:
Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is designed to enable highly potent and conformal alpha-irradiation of solid tumors by intratumoral delivery of radium-224 impregnated sources.
Lead Product(s): Radium-224
Therapeutic Area: Oncology Product Name: Alpha Dart
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2022
Details:
Alpha DaRT (Radium-224) is designed to enable highly potent and conformal alpha-irradiation of solid tumors by intratumoral insertion of radium-224 impregnated seeds.
Lead Product(s): Radium-224
Therapeutic Area: Oncology Product Name: Alpha Dart
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 08, 2022
Details:
The investigators will examine whether such a synergy exists between Alpha DaRT, immune checkpoint inhibitors, and biological treatments that inhibit DNA repair in a pre-clinical setting.
Lead Product(s): Radium-224
Therapeutic Area: Oncology Product Name: Alpha Dart
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: The University of Texas MD Anderson Cancer Center
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 20, 2022
Details:
Radspherin®, a novel alpha-emitting radioactive microsphere suspension designed for treatment of metastatic cancers in body cavities and its versatility allows it to be deployed for the treatment of a variety of cancer indications.
Lead Product(s): Radium-224
Therapeutic Area: Oncology Product Name: Radspherin
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 20, 2021
Details:
7MBq dose of Radspherin® determined to be safe, and approved by the SMC as the recommended clinical dose for repeated injection and expansion cohorts of RAD-18-002 study.
Lead Product(s): Radium-224
Therapeutic Area: Oncology Product Name: Radspherin
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 09, 2021
Details:
The phase 1 dose escalation trial is designed to assess the dose, safety and tolerability of Radspherin® administered into the intraperitoneal cavity in subjects with peritoneal carcinomatosis from colorectal carcinoma following complete cytoreductive surgery and HIPEC.
Lead Product(s): Radium-224
Therapeutic Area: Oncology Product Name: Radspherin
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 29, 2020
Details:
According to the new arrangement, Medison shall also have the exclusive rights to commercialize and distribute the Alpha DaRT in Canada including Israel.
Lead Product(s): Radium-224
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Medison
Deal Size: $9.0 million Upfront Cash: Undisclosed
Deal Type: Agreement April 07, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
